Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13 | Zendy

Anup Aggarwal | Zendy; Maloy Kumar Parai | Zendy; N.D. Shetty | Zendy; Deeann Wallis | Zendy; Lisa K. Woolhiser | Zendy; Courtney Hastings | Zendy; Noton K. Dutta | Zendy; Stacy Galaviz | Zendy; Ramesh Dhakal | Zendy; Rupesh Shrestha | Zendy; Shoko Wakabayashi | Zendy; Chris Walpole | Zendy; David J. Matthews | Zendy; David Floyd | Zendy; Paul Scullion | Zendy; Jennifer Riley | Zendy; Ola Epemolu | Zendy; Suzanne Norval | Zendy; Thomas Snavely | Zendy; Gregory T. Robertson | Zendy; Eric J. Rubin | Zendy; Thomas R. Ioerger | Zendy; F A Sirgel | Zendy; Ruben van der Merwe | Zendy; Paul D. van Helden | Zendy; Peter M. Keller | Zendy; Erik C. Böttger | Zendy; Petros C. Karakousis | Zendy; Anne J. Lenaerts | Zendy; James C. Sacchettini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13

Author(s) -

Anup Aggarwal,

Maloy Kumar Parai,

N.D. Shetty,

Deeann Wallis,

Lisa K. Woolhiser,

Courtney Hastings,

Noton K. Dutta,

Stacy Galaviz,

Ramesh Dhakal,

Rupesh Shrestha,

Shoko Wakabayashi,

Chris Walpole,

David J. Matthews,

David Floyd,

Paul Scullion,

Jennifer Riley,

Ola Epemolu,

Suzanne Norval,

Thomas Snavely,

Gregory T. Robertson,

Eric J. Rubin,

Thomas R. Ioerger,

F A Sirgel,

Ruben van der Merwe,

Paul D. van Helden,

Peter M. Keller,

Erik C. Böttger,

Petros C. Karakousis,

Anne J. Lenaerts,

James C. Sacchettini

Publication year - 2017

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2017.06.025

Subject(s) - polyketide synthase , biology , mycobacterium tuberculosis , tuberculosis , rifampicin , in vivo , microbiology and biotechnology , polyketide , isoniazid , drug resistance , drug , pharmacology , antibiotics , enzyme , biochemistry , biosynthesis , medicine , genetics , pathology

Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action. We have used structure-guided methods to develop a lead molecule that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis. Our lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clinical isolates of M. tuberculosis. In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin. TAM16 has excellent pharmacological and safety profiles, and the frequency of resistance for TAM16 is ∼100-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection. PAPERCLIP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research